Qelbree (Viloxazine Extended-Release) Dosing
For children aged 6-11 years, start Qelbree at 100 mg once daily and titrate by 100 mg weekly increments up to a maximum of 400 mg/day; for adolescents aged 12-17 years and adults, start at 200 mg once daily and titrate by 100-200 mg weekly increments up to a maximum of 600 mg/day. 1, 2
Pediatric Dosing (Ages 6-17 Years)
Children (6-11 years)
- Starting dose: 100 mg once daily 2
- Titration: Increase by 100 mg increments at weekly intervals based on response and tolerability 2
- Maximum dose: 400 mg/day 2
- Typical maintenance dose: Most children in long-term studies used 300 mg/day as their modal dose 2
Adolescents (12-17 years)
- Starting dose: 200 mg once daily 2
- Titration: Increase by 100-200 mg increments at weekly intervals 1, 2
- Maximum dose: 600 mg/day 1, 2
- Typical maintenance dose: Most adolescents in long-term studies used 400 mg/day as their modal dose 2
Adult Dosing (Ages 18-65 Years)
- Starting dose: 200 mg once daily 3, 4
- Titration: Adjust between 200-600 mg/day at weekly intervals to achieve optimal efficacy and tolerability 3, 4
- Maximum dose: 600 mg/day 1, 3
- Typical maintenance dose: 73% of adults in long-term studies used doses ≥400 mg/day, with 36% using the maximum 600 mg/day dose 3
- Mean effective dose in clinical trials: 504 mg/day 4
Administration Guidelines
- Frequency: Once daily oral administration 5, 6
- Formulation: Extended-release capsules 2, 5
- Onset of action: Therapeutic effects typically observed within 1-2 weeks, which is faster than atomoxetine's 4-week onset 6
- Dose optimization period: Allow 12 weeks for full dose optimization before determining final maintenance dose 2
Clinical Considerations
Common pitfall: Underdosing is a frequent error—most patients require doses at the higher end of the range for optimal efficacy. In adult trials, 73% of participants needed ≥400 mg/day during maintenance treatment 3. Do not hesitate to titrate to maximum doses if lower doses are inadequate and well-tolerated.
Monitoring timeline: Assess response every 2-3 weeks during titration, as significant improvements in ADHD symptoms can be detected as early as week 2 of treatment 4. Continue monitoring every 3 months during maintenance therapy 2.